Twin City Private Wealth LLC Buys 2,608 Shares of Pfizer Inc. (NYSE:PFE)

Twin City Private Wealth LLC raised its stake in Pfizer Inc. (NYSE:PFE) by 6.5% in the 1st quarter, according to its most recent disclosure with the SEC. The fund owned 42,740 shares of the biopharmaceutical company’s stock after purchasing an additional 2,608 shares during the quarter. Twin City Private Wealth LLC’s holdings in Pfizer were worth $1,083,000 at the end of the most recent quarter.

Other hedge funds have also recently made changes to their positions in the company. William B. Walkup & Associates Inc. lifted its position in Pfizer by 1.2% in the 4th quarter. William B. Walkup & Associates Inc. now owns 39,368 shares of the biopharmaceutical company’s stock worth $1,044,000 after buying an additional 454 shares in the last quarter. Members Trust Co lifted its position in Pfizer by 2.1% in the 1st quarter. Members Trust Co now owns 23,175 shares of the biopharmaceutical company’s stock worth $587,000 after buying an additional 467 shares in the last quarter. Sutton Place Investors LLC lifted its position in Pfizer by 5.6% in the 1st quarter. Sutton Place Investors LLC now owns 8,833 shares of the biopharmaceutical company’s stock worth $224,000 after buying an additional 472 shares in the last quarter. Bellevue Group AG raised its holdings in shares of Pfizer by 0.3% during the 4th quarter. Bellevue Group AG now owns 141,560 shares of the biopharmaceutical company’s stock valued at $3,756,000 after purchasing an additional 485 shares in the last quarter. Finally, Gould Capital LLC raised its holdings in shares of Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company’s stock valued at $27,000 after purchasing an additional 493 shares in the last quarter. 68.36% of the stock is owned by hedge funds and other institutional investors.

Pfizer Price Performance

Shares of Pfizer stock opened at $24.69 on Wednesday. The company has a debt-to-equity ratio of 0.64, a quick ratio of 0.96 and a current ratio of 1.26. The firm’s 50-day simple moving average is $24.39 and its 200-day simple moving average is $24.54. Pfizer Inc. has a twelve month low of $20.92 and a twelve month high of $30.43. The firm has a market cap of $140.37 billion, a P/E ratio of 17.89, a price-to-earnings-growth ratio of 0.85 and a beta of 0.52.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 earnings per share for the quarter, beating the consensus estimate of $0.58 by $0.20. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The business had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the business earned $0.60 EPS. The firm’s revenue was up 10.3% on a year-over-year basis. As a group, research analysts expect that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be given a dividend of $0.43 per share. This represents a $1.72 annualized dividend and a dividend yield of 7.0%. The ex-dividend date is Friday, July 25th. Pfizer’s payout ratio is 124.64%.

Analysts Set New Price Targets

A number of research analysts have recently weighed in on the stock. HSBC cut their price target on shares of Pfizer from $27.00 to $26.00 and set a “buy” rating on the stock in a report on Monday, May 19th. Leerink Partners lowered their target price on shares of Pfizer from $28.00 to $26.00 and set a “market perform” rating on the stock in a research note on Wednesday, April 30th. Wolfe Research raised their target price on shares of Pfizer from $22.00 to $23.00 and gave the company an “underperform” rating in a research note on Wednesday, April 30th. Jefferies Financial Group raised their target price on shares of Pfizer from $32.00 to $33.00 and gave the company a “buy” rating in a research note on Wednesday, May 21st. Finally, Bank of America raised their target price on shares of Pfizer from $26.00 to $27.00 and gave the company a “neutral” rating in a research note on Wednesday, April 30th. One research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, six have issued a buy rating and three have assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $28.28.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.